Cardiff Lexington Corp Annual Report - Your 2025 Investor Update

This summary provides a clear, concise overview of Cardiff Lexington Corp.'s performance for the year ending December 31, 2025, based on its latest SEC filing. It aims to help you understand the company's key developments and financial standing as you consider it for your portfolio.

Business Overview

Cardiff Lexington operates as a "smaller reporting company," a designation for firms with a public float (the value of freely traded shares) under $250 million, allowing them to follow slightly different reporting rules than larger corporations. As of June 30, 2025, the market value of its common stock held by non-affiliates totaled approximately $45.4 million. By March 9, 2026, the company reported 15.16 million shares of common stock outstanding.

The company primarily operates in two key sectors:

• Healthcare: Cardiff Lexington acquires and manages healthcare-related businesses, often targeting those with established revenue streams or growth potential. This includes areas like medical device distribution, healthcare services, or technology solutions.
• Real Estate: Its real estate operations typically involve acquiring, developing, and managing commercial or residential properties, or investing in related ventures.

The company's stated strategy often involves growth through strategic acquisitions within these core segments, aiming to build a diversified portfolio.

Risk Factors

Cardiff Lexington Corp. faces several key risks:

• Financial Health: Achieving profitability and generating positive cash flow from operations remains a primary concern, especially given historical net losses and the ongoing need for financing.
• Acquisition Strategy: While growth through acquisition is a stated goal, it carries inherent risks such as integration challenges, overpaying for targets, and potential impairment of goodwill if acquisitions do not perform as expected.
• Capital Structure & Dilution: The ongoing conversion of preferred stock and the equity incentive plan pose a persistent risk of further dilution for common shareholders.
• Reporting Reliability: The 2024 restatement underscores the need to scrutinize the company's financial reporting and internal controls.
• Market Conditions: Performance in the Healthcare and Real Estate sectors is subject to broader economic conditions, regulatory changes, and competitive pressures.

Management Discussion

Key developments and strategic shifts for 2025 include:

1. Exiting RedRock Operations:
   • Cardiff Lexington divested its RedRock segment, now classified as "discontinued operations." This strategic move, initiated with a settlement in early 2024, aims to streamline the company's focus on its core Healthcare and Real Estate businesses.
   • Financial Impact: The RedRock discontinuation aims to reduce future operational complexities and potentially improve overall profitability by eliminating a non-core, underperforming asset.
2. Financial Restatement in 2024:
   • The company completed a significant restatement adjustment in 2024 to correct errors in previously issued financial statements.
   • Impact: While the company implemented new controls to prevent recurrence, investors should carefully review the nature and magnitude of these adjustments to assess the reliability of past financial reporting.
3. Increased Common Shares & Potential Dilution:
   • Throughout 2024 and 2025, Cardiff Lexington converted a substantial number of preferred shares (including Series B, C, E, I, N, X, Y, R) into common stock, significantly increasing common shares outstanding.
   • Impact: This conversion activity, along with other share issuances, contributed to an increase in common shares outstanding year-over-year. While it simplifies the capital structure, it also results in dilution for existing common shareholders. This means each share represents a smaller percentage of company ownership and can reduce earnings per share if overall profits do not grow proportionally.
4. Active Financing Activities:
   • Cardiff Lexington actively raised capital during 2025. It issued new promissory notes and convertible notes payable, primarily funding working capital, supporting ongoing operations, and potentially financing future acquisitions.
   • Debt Profile: As of year-end, the company's total debt included an existing SBA loan from 2020. The terms of new notes vary, with maturity dates extending from 2026 to 2029. This increased debt implies higher interest expenses and repayment obligations.
5. Equity Incentive Plan:
   • In 2024, the company established an Equity Incentive Plan, reserving shares of common stock for issuance. In 2025, it granted restricted common stock units and stock options to key employees and board members.
   • Purpose & Impact: This plan aims to align management and employee incentives with shareholder interests. However, future vesting and exercise of these awards could further dilute common stock if all reserved shares are issued.

Financial Health

The ongoing conversion of preferred shares into common stock impacts the capital structure and financial leverage.

Future Outlook

Cardiff Lexington continues to focus its strategy on growth through strategic acquisitions within its core Healthcare and Real Estate sectors. The 2025 divestiture of the RedRock segment is a key step to streamline operations, focus resources on core businesses, and improve overall profitability. Management aims to achieve sustained profitability and generate positive cash flow from operations to strengthen the company's financial position.

What This Means for You as an Investor

Cardiff Lexington Corp. is a company in transition, actively reshaping its business and capital structure. The discontinuation of RedRock signals a clearer focus. However, the financial restatement and ongoing dilution from share conversions remain significant factors for investors to consider.

For an informed investment decision, consider these steps:

• Deeply analyze the full 10-K: Understand the specifics of the restatement, the terms of its debt, and the detailed breakdown of its Healthcare and Real Estate operations.
• Monitor financial performance: Look for consistent revenue growth, improving margins, and a clear path to sustained profitability and positive cash flow in its continuing operations.
• Assess management's execution: Evaluate management's ability to successfully integrate acquisitions and effectively manage debt obligations.

This summary provides a starting point, but thorough due diligence is essential for any investment decision.